Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 73

1.

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.

Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteză M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM; TRILOGY ACS Investigators.

N Engl J Med. 2012 Oct 4;367(14):1297-309. doi: 10.1056/NEJMoa1205512. Epub 2012 Aug 25.

2.

Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study.

Charlot M, Nielsen LH, Lindhardsen J, Ahlehoff O, Olsen AM, Hansen ML, Hansen PR, Madsen JK, Køber L, Gislason GH, Torp-Pedersen C.

Eur Heart J. 2012 Oct;33(20):2527-34. doi: 10.1093/eurheartj/ehs202. Epub 2012 Jul 12.

PMID:
22798561
3.

Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?

Ruiz-Nodar JM, Marín F, Roldán V, Valencia J, Manzano-Fernández S, Caballero L, Hurtado JA, Sogorb F, Valdés M, Lip GY.

Circ Cardiovasc Interv. 2012 Aug 1;5(4):459-66. doi: 10.1161/CIRCINTERVENTIONS.112.968792. Epub 2012 Jul 10.

4.

Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).

Patti G, Pasceri V, D'Antonio L, D'Ambrosio A, Macrì M, Dicuonzo G, Colonna G, Montinaro A, Di Sciascio G.

Am J Cardiol. 2012 Aug 15;110(4):478-84. doi: 10.1016/j.amjcard.2012.04.017. Epub 2012 May 12.

PMID:
22583760
5.

Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.

Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F, Colombo F, Tebaldi M, Fucà G, Kubbajeh M, Cangiano E, Minarelli M, Scalone A, Cavazza C, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R; Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators.

Circulation. 2012 Apr 24;125(16):2015-26. doi: 10.1161/CIRCULATIONAHA.111.071589. Epub 2012 Mar 21.

6.

Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.

Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS.

Circulation. 2012 Jan 24;125(3):505-13. doi: 10.1161/CIRCULATIONAHA.111.059022. Epub 2011 Dec 16.

7.

Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.

Kastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, Laugwitz KL, Pache J, Ott I, Hausleiter J, Seyfarth M, Gick M, Antoniucci D, Schömig A, Berger PB, Mehilli J; ISAR-REACT 4 Trial Investigators.

N Engl J Med. 2011 Nov 24;365(21):1980-9. doi: 10.1056/NEJMoa1109596. Epub 2011 Nov 13.

8.

Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation.

Schmidt M, Johansen MB, Robertson DJ, Maeng M, Kaltoft A, Jensen LO, Tilsted HH, Bøtker HE, Sørensen HT, Baron JA.

Aliment Pharmacol Ther. 2012 Jan;35(1):165-74. doi: 10.1111/j.1365-2036.2011.04890.x. Epub 2011 Nov 4.

9.

Low-dose versus high-dose aspirin after percutaneous coronary intervention: analysis from the guthrie health off-label StenT (GHOST) registry.

Harjai KJ, Shenoy C, Orshaw P, Usmani S, Singh M, Boura J, Mehta RH.

J Interv Cardiol. 2011 Aug;24(4):307-14. doi: 10.1111/j.1540-8183.2011.00627.x. Epub 2011 Jul 25.

PMID:
21790788
10.

Comparison of efficacy and safety of a standard versus a loading dose of clopidogrel for acute myocardial infarction in patients ≥ 75 years of age (from the FAST-MI registry).

Puymirat E, Aïssaoui N, Coste P, Dentan G, Bataille V, Drouet E, Mulak G, Carrié D, Blanchard D, Simon T, Danchin N.

Am J Cardiol. 2011 Sep 15;108(6):755-9. doi: 10.1016/j.amjcard.2011.04.028. Epub 2011 Jul 2.

PMID:
21726837
11.

Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.

Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS, Horrow J, Harrington RA, Wallentin L; PLATO Investigators.

Circulation. 2011 Aug 2;124(5):544-54. doi: 10.1161/CIRCULATIONAHA.111.047498. Epub 2011 Jun 27.

12.

Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome.

Persson J, Lindbäck J, Hofman-Bang C, Lagerqvist B, Stenestrand U, Samnegard A.

EuroIntervention. 2011 Apr;6(9):1046-52, 8-9. doi: 10.4244/EIJV6I9A183.

PMID:
21518675
13.

Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent (GHOST) investigators.

Harjai KJ, Shenoy C, Orshaw P, Usmani S, Boura J, Mehta RH.

Circ Cardiovasc Interv. 2011 Apr 1;4(2):162-70. doi: 10.1161/CIRCINTERVENTIONS.110.958884. Epub 2011 Mar 8.

14.

Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation.

Rossini R, Capodanno D, Musumeci G, Lettieri C, Lortkipanidze N, Romano M, Nijaradze T, Tarantini G, Cicorella N, Sirbu V, Guagliumi G, Rosiello R, Valsecchi O, Gavazzi A.

Coron Artery Dis. 2011 May;22(3):199-205. doi: 10.1097/MCA.0b013e328343b03a.

PMID:
21358542
15.

Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry.

Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, Lardoux H, Coste P, Lefèvre T, Drouet E, Mulak G, Bataille V, Ferrières J, Verstuyft C, Danchin N.

Circulation. 2011 Feb 8;123(5):474-82. doi: 10.1161/CIRCULATIONAHA.110.965640. Epub 2011 Jan 24.

16.

Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors.

Valkhoff VE, 't Jong GW, Van Soest EM, Kuipers EJ, Sturkenboom MC.

Aliment Pharmacol Ther. 2011 Jan;33(1):77-88. doi: 10.1111/j.1365-2036.2010.04485.x. Epub 2010 Oct 19.

17.

Intravenous enoxaparin versus unfractionated heparin in unselected patients undergoing percutaneous coronary interventions: the Zurich enoxaparin versus unfractionated heparin in PCI study (ZEUS).

Bertel O, Ramsay D, Wettstein T, Kurz DJ, Stettler I, Straumann E, Frielingsdorf J, Maurer D, Naegeli B.

EuroIntervention. 2010 Aug;6(3):407-12. doi: 10.4244/EIJV6I3A67.

PMID:
20884422
18.

Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study.

Charlot M, Ahlehoff O, Norgaard ML, Jørgensen CH, Sørensen R, Abildstrøm SZ, Hansen PR, Madsen JK, Køber L, Torp-Pedersen C, Gislason G.

Ann Intern Med. 2010 Sep 21;153(6):378-86. doi: 10.7326/0003-4819-153-6-201009210-00005. Erratum in: Ann Intern Med. 2011 Jan 4;154(1):76.

PMID:
20855802
19.

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.

CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S.

N Engl J Med. 2010 Sep 2;363(10):930-42. doi: 10.1056/NEJMoa0909475. Erratum in: N Engl J Med. 2010 Oct 14;363(16):1585.

20.

Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial.

FUTURA/OASIS-8 Trial Group, Steg PG, Jolly SS, Mehta SR, Afzal R, Xavier D, Rupprecht HJ, López-Sendón JL, Budaj A, Diaz R, Avezum A, Widimsky P, Rao SV, Chrolavicius S, Meeks B, Joyner C, Pogue J, Yusuf S.

JAMA. 2010 Sep 22;304(12):1339-49. doi: 10.1001/jama.2010.1320. Epub 2010 Aug 31.

PMID:
20805623

Supplemental Content

Support Center